Phase 3 N=349 FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Pulmonary Hypertension
Primary: Six Minute Walk Distance (6MWD) — 339; 350; 343; 370 meters — p=0.0125
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=653 Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (A1C) — -1.32; -1.42 percent
Phase 3 N=1,630 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Meningococcal Infections
Primary: Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine — 98…
Phase 3 N=540 Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Metastases, Brain
Primary: Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse — 8; 12 participants — p=0.360
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 3 N=340 Efficacy of Esomeprazole in Patients With Frequent Heartburn
Heartburn
Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment — 43.32; 29.44 Percentage
Phase 3 N=6 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
Acute Lymphoblastic Leukemia · Acute Myelocytic Leukemia · Chronic Myelocytic Leukemia
Primary: Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by…
Phase 3 N=1,029 Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Number of Patients With Treatment Failure — 203; 262; 287; 225 number of patients — p=0.0020
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects
Phase 3 N=167 NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation
Heart Diseases · Arrhythmia · Atrial Fibrillation
Primary: The Percentage of Chronic Success of the NAVISTAR THERMOCOOL Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (PAF) — 66; 16 Percentage of…
Phase 3 N=315 Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index© Questionnaire Score — 41.48; 38.27; 40.28; 40.18 Score on a scale
Phase 3 N=100 A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Neoplasms
Primary: Percentage of Participants Who Achieved Pain Control — 84.0; 98.0 Percentage of Participants
Phase 3 N=44 Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
Multifocal Motor Neuropathy
Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms
Phase 3 N=46 A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Serum Progesterone Level — 0.21; 0.57; 0.22; NA ng/mL
Phase 3 N=561 Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12 — 25.41; 25.38; 24.79; 24.72 mm Hg